Literature DB >> 24874457

Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: a prospective study.

Aranzazu Jauregui-Amezaga1, María López-Cerón, Montserrat Aceituno, Mireya Jimeno, Cristina Rodríguez de Miguel, Susana Pinó-Donnay, Michel Zabalza, Miquel Sans, Elena Ricart, Ingrid Ordás, Begoña González-Suárez, Miriam Cuatrecasas, Josep Llach, Julian Panés, María Pellise.   

Abstract

BACKGROUND: The aim of this study was to determine the accuracy of advanced endoscopy for prediction of relapse in ulcerative colitis, in comparison with serum and fecal biomarkers.
METHODS: Patients with ulcerative colitis with sustained clinical remission defined as absence of blood in stool for a minimum of 3 months and Mayo endoscopic subscore of 0 were included. High-resolution rectosigmoidoscopy was performed at baseline and at the end of study (week 52 or relapse), assessing mucosal pit pattern by chromoendoscopy and narrow band imaging as well as vascular pattern by narrow band imaging. Histology was evaluated at baseline and at the end of the study. Follow-up for 1 year or until relapse with clinical evaluations and serum and fecal biomarkers every 3 months was established. Relapse was defined as presence of blood in stool and a Mayo endoscopic subscore ≥1 with histologic confirmation.
RESULTS: Seventeen out of 64 patients (27%) relapsed during the follow-up period. Baseline clinical characteristics in patients who relapsed and those who did not were similar. Neither pit or vascular pattern nor histology was significantly different between relapsers and nonrelapsers. Among serum biomarkers, high platelet count was significantly associated with higher relapse rates. Fecal calprotectin was predictor of relapse within 3- and 12-month period with high specificity but low sensitivity.
CONCLUSIONS: Advanced endoscopy and histology do not predict relapse over 1-year period in patients with ulcerative colitis. Fecal calprotectin can predict relapse in 3- and 12-month period with low accuracy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24874457     DOI: 10.1097/MIB.0000000000000069

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  24 in total

1.  Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.

Authors:  Antonio Tursi; Walter Elisei; Marcello Picchio; GianMarco Giorgetti; Giovanni Brandimarte
Journal:  Dig Dis Sci       Date:  2014-12-02       Impact factor: 3.199

Review 2.  Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.

Authors:  Anke Heida; K T Park; Patrick F van Rheenen
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

3.  Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Authors:  Hyuk Yoon; Sushrut Jangi; Parambir S Dulai; Brigid S Boland; Larry J Prokop; Vipul Jairath; Brian G Feagan; William J Sandborn; Siddharth Singh
Journal:  Gastroenterology       Date:  2020-06-22       Impact factor: 22.682

Review 4.  Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis.

Authors:  Sunhee Park; Tsion Abdi; Mark Gentry; Loren Laine
Journal:  Am J Gastroenterol       Date:  2016-10-11       Impact factor: 10.864

5.  Faecal calprotectin is a surrogate marker of biliary inflammation in primary sclerosing cholangitis associated inflammatory bowel disease.

Authors:  Polychronis Pavlidis; Deepak Joshi; Yasser El Sherif; Ben Warner; Shraddha Gulati; James Alexander; Gemma Cross; Tracy Dew; Hadil Abu Arqoub; John Devlin; Michael Heneghan; Patrick Dubois; Ingvar Bjarnason; Nick Powell; Bu'Hussain Hayee
Journal:  Frontline Gastroenterol       Date:  2022-03-18

Review 6.  How to predict clinical relapse in inflammatory bowel disease patients.

Authors:  Elisa Liverani; Eleonora Scaioli; Richard John Digby; Matteo Bellanova; Andrea Belluzzi
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 7.  Imaging Inflammation - From Whole Body Imaging to Cellular Resolution.

Authors:  Tuula Peñate Medina; Jan Philip Kolb; Gereon Hüttmann; Robert Huber; Oula Peñate Medina; Linh Ha; Patricia Ulloa; Naomi Larsen; Arianna Ferrari; Magdalena Rafecas; Mark Ellrichmann; Mariya S Pravdivtseva; Mariia Anikeeva; Jana Humbert; Marcus Both; Jennifer E Hundt; Jan-Bernd Hövener
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

8.  Histological Inflammation in the Endoscopically Uninflamed Mucosa is Associated With Worse Outcomes in Limited Ulcerative Colitis.

Authors:  Catarina Geraldes de Frias Gomes; Alexandra Sofia Ribeiro de Almeida; Catarina Callé Lucas Mendes; Pierre Ellul; Johan Burisch; Tiffany Buhagiar; Abigail Attard; Bobby Lo; Ryan C Ungaro; Bárbara Tonilhas da Silva Morão; Catarina Ferreira Gouveia; Joana Milheiro Delgado de Carvalho E Branco; Jaime Manuel Martins Pereira Rodrigues; Cristina Teixeira; Maria Francisca Faria Dias de Castro; Gonçalo Filipe Domingos Nunes; Mariana Brito; Marília Cristina de Sousa Antunes; Paula Maria Ferreira Brinca Borralho Nunes; Joana Maria Tinoco da Silva Torres
Journal:  Inflamm Bowel Dis       Date:  2022-03-02       Impact factor: 7.290

9.  Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter study.

Authors:  Triana Lobatón; Talat Bessissow; Alexandra Ruiz-Cerulla; Gert De Hertogh; Raf Bisschops; Jordi Guardiola; Gert Van Assche; Severine Vermeire; Marc Ferrante
Journal:  United European Gastroenterol J       Date:  2018-01-08       Impact factor: 4.623

Review 10.  Endoscopic and Histologic Predictors of Outcomes in Pediatric Ulcerative Colitis-Caveat Emptor.

Authors:  Lorraine Stallard; Séamus Hussey
Journal:  Front Pediatr       Date:  2021-06-23       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.